about this reading room.
A casebook of one investigational molecule
What this site is, what it is not, how the writing is sourced, and the editorial standards that govern it.
What this site is
Retatrutide Prescribed is a casebook of one investigational molecule: a careful reading of the peer-reviewed retatrutide literature, kept the way a clinician might keep a casebook — one subject, read closely, sourced primarily, updated when new published evidence earns the entry. Five reading pages and a reference list, written to be understood.
A casebook is a reading, not a practice. No one here diagnoses, treats, or prescribes; there is no clinic, no dispensary, and nothing on these pages is sold, supplied, or sourced. The writing is commentary on published science, and every measured claim is cited.
What the domain name does not mean
The word 'prescribed' in the domain is a framing, not a service — a position this casebook takes toward the literature. It reads the molecule as if it were already a prescriptive object in the medical conversation: a thing one could imagine being prescribed, and which therefore deserves the same careful reading any prescribable molecule would get.
It is not a claim that this site writes prescriptions or refers to a prescriber. Retatrutide cannot be prescribed in any jurisdiction today, by any clinician, through any pharmacy. This is a casebook, not a clinic, and not a road to one.
How the writing is sourced
Every quantitative claim rests on a primary publication, a registered trial record, or a clearly labeled sponsor topline. The bibliography lives on /references with full metadata, DOIs where they exist, and links out to PubMed, ClinicalTrials.gov, or the journal of record.
Secondary sources — conference coverage, say — are used only where the underlying primary paper isn't yet available, and are labeled as such. Forum posts, vendor copy, and anonymous web content are not cited. Where the trial record doesn't yet answer a question, the casebook leaves the line open and says so.
Editorial standards
The voice is clinical but approachable: exact on the science, plain in the language, calm about the uncertainty. Where a trial reports a number, the number is reported with its source. Where the trials are silent, the silence is named rather than filled.
Brand-marketed competitor products are never named by brand; the comparator molecules in the incretin field appear only under their International Nonproprietary Names. And the casebook does not instruct — 'should' is reserved for describing what published authors recommend, never for telling a reader what to do.
Affiliation and conflicts
This casebook is not affiliated with Eli Lilly, the sponsor of retatrutide's development, nor with any other manufacturer, compounding pharmacy, telehealth provider, research-chemical vendor, or patient-recruitment outfit. No payment, free product, or consideration of any kind is accepted from any commercial party named in the coverage.
It is an unaffiliated editorial effort. It manufactures nothing, sells nothing, and distributes nothing, and it holds no commercial relationship with anyone in this space. The footer disclaimer on every page is the standing contract.
A small note from the editor
Most of what gets written about investigational molecules reads either like a press release or like the comment section under one. Neither serves a reader. The small ambition here is to set one molecule on a quiet shelf, read its trial record with care, and leave the page in a state where a curious person can pick it up and learn something real before deciding what to do with it.
If there's an error of fact, or a published result the casebook has missed, /contact is where to say so.